儿童和青少年 5-17 岁人群延长初级系列接种间隔时间后 BNT162b2 的有效性。
Effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5-17.
机构信息
Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong.
Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Shatin, Hong Kong.
出版信息
Nat Commun. 2023 Apr 3;14(1):1845. doi: 10.1038/s41467-023-37556-z.
Extended intervals between the first and second doses of mRNA Covid-19 vaccines may reduce the risk of myocarditis in children and adolescents. However, vaccine effectiveness after this extension remains unclear. To examine this potential variable effectiveness, we conducted a population-based nested case-control study of children and adolescents aged 5-17 years who had received two doses of BNT162b2 in Hong Kong. From January 1 to August 15, 2022, 5396 Covid-19 cases and 202 Covid-19 related hospitalizations were identified and matched with 21,577 and 808 controls, respectively. For vaccine recipients with extended intervals [≥28 days, adjusted odds ratio 0.718, 95% Confidence Interval: 0.619, 0.833] there was a 29.2%-reduced risk of Covid-19 infection compared to those with regular intervals (21-27 days). If the threshold was set at eight weeks, the risk reduction was estimated at 43.5% (aOR 0.565, 95% CI: 0.456, 0.700). In conclusion, longer dosing intervals for children and adolescents should be considered.
mRNA 新冠疫苗首剂和第二剂的间隔时间延长可能会降低儿童和青少年心肌炎的风险。然而，这种延长后的疫苗有效性尚不清楚。为了研究这种潜在的可变有效性，我们对在香港接种了两剂 BNT162b2 的 5-17 岁儿童和青少年进行了一项基于人群的巢式病例对照研究。2022 年 1 月 1 日至 8 月 15 日，共发现 5396 例新冠病例和 202 例与新冠相关的住院病例，并分别与 21577 例和 808 例对照进行了匹配。对于间隔时间延长（≥28 天）的疫苗接种者，与间隔时间为 21-27 天的疫苗接种者相比，新冠感染的风险降低了 29.2%（调整后的优势比 0.718，95%置信区间：0.619，0.833）。如果将阈值设定为八周，则估计风险降低 43.5%（aOR 0.565，95%CI：0.456，0.700）。总之，应该考虑为儿童和青少年延长接种间隔。
Zotero 插件